A clinical trial is a research study that tests a medical treatment, drug, device, or preventive measure in human volunteers to find out whether it’s safe and effective. These studies are the required pathway for nearly every new medication or therapy before it can reach the public. The process from first human test to regulatory approval takes a median of 7.3 years, and only about 10 to 14 percent of drugs that enter clinical testing ever make it to approval.
What Clinical Trials Actually Do
At its core, a clinical trial assigns participants to a specific intervention, then measures what happens. That intervention could be a new drug, a combination of existing drugs, a surgical technique, a medical device, a behavioral program, or even a screening method. The goal is always the same: gather real evidence about whether something works and whether it’s safe enough to justify its use.
Not all clinical trials test treatments for people who are already sick. Prevention trials enroll people who don’t have a disease to see if a therapy can stop it from developing. Screening trials test whether a detection method can catch a disease early, before symptoms appear. Treatment trials, the most common type, test new or improved ways to treat an existing condition. Quality-of-life trials look at ways to improve comfort and daily functioning for people living with a chronic illness.
The Four Phases of Testing
New drugs move through a structured series of phases, each designed to answer different questions. A drug must clear each phase before advancing to the next.
Phase 1 is the first time a treatment is given to people. It typically involves 20 to 100 volunteers and lasts several months. The primary goal isn’t to cure anyone. Researchers are looking for safe dosage ranges and identifying side effects. Sometimes healthy volunteers participate; other times, participants already have the condition the drug targets.
Phase 2 expands the study to up to several hundred people who have the disease or condition. This phase, which can last several months to two years, focuses on whether the treatment actually works while continuing to track side effects. Many drugs fail here because they don’t perform well enough to justify further testing.
Phase 3 is the large-scale test. Between 300 and 3,000 volunteers participate over one to four years. Researchers compare the new treatment against existing standard treatments or placebos to confirm effectiveness and monitor for less common adverse reactions. Successful Phase 3 results are typically what a regulatory agency needs to consider approving a drug.
Phase 4 happens after a drug is already on the market. These studies track safety and effectiveness in thousands of people over longer periods, catching rare side effects that smaller studies couldn’t detect. A Phase 4 trial might also explore whether an approved drug works for additional conditions.
How Bias Is Minimized
The gold standard in clinical trial design is the randomized, double-blind, placebo-controlled study. Each of those terms describes a specific layer of protection against skewed results.
Randomization means participants are assigned to the treatment group or the control group by chance, not by a doctor’s decision. This prevents the groups from being stacked in ways that could distort the outcome. The control group might receive a placebo (an inactive substance that looks identical to the real treatment) or the current standard therapy, giving researchers a baseline for comparison.
In a double-blind study, neither the participants nor the researchers know who is receiving the real treatment and who is receiving the placebo until the trial is over. This eliminates the possibility that expectations, whether a patient’s hope or a researcher’s optimism, influence the results. When both layers of blinding are combined with randomization, the findings are far more likely to reflect the true effect of the treatment rather than coincidence or psychological factors.
Who Can Participate
Every clinical trial has eligibility criteria that define exactly who can and cannot enroll. Inclusion criteria specify what characteristics a participant must have, such as a particular stage of disease, age range, or specific health markers. Exclusion criteria rule out people whose other medical conditions or current medications might interfere with the results or put them at additional risk.
These criteria exist to create a well-defined study population where the drug’s effect can be clearly measured. But overly narrow criteria have historically been a problem. Trials have often underrepresented women, older adults, and racial and ethnic minorities, which means approved drugs sometimes lack evidence about how they perform in large portions of the population. The FDA now requires sponsors of certain clinical studies to submit diversity action plans describing how they will improve enrollment of underrepresented groups.
Safety Protections for Participants
Before any clinical trial can begin, it must be reviewed and approved by an Institutional Review Board, an independent group formally designated to protect the rights and welfare of research participants. The board examines the study’s design, its risks, and all materials participants will see, including the consent documents. It has the authority to approve, require changes to, or reject a study entirely, and it continues to monitor the trial periodically after it starts.
Informed consent is the cornerstone of participant protection. Before joining a trial, you must receive a detailed explanation of what the study involves, how long it will last, what risks and discomforts are foreseeable, what benefits you might expect, and what alternative treatments exist outside the study. You must also be told whether compensation or medical treatment is available if you’re injured during the research, how your personal information will be kept confidential, and who to contact with questions or concerns.
One point that’s non-negotiable: participation is always voluntary. You can refuse to join without any penalty, and you can withdraw at any time without losing access to benefits you’re otherwise entitled to. No one can pressure you into staying in a study, and if significant new safety information emerges during the trial, researchers are required to share it with you so you can decide whether to continue.
Why Most Drugs Don’t Make It
The path from Phase 1 to approval is long, and most candidates don’t survive it. An analysis of nearly 20,000 clinical trials conducted by 18 major pharmaceutical companies between 2006 and 2022 found that the average likelihood of a drug going from Phase 1 to its first FDA approval was 14.3 percent. Some companies achieved rates as high as 23 percent, while others fell as low as 8 percent. Earlier industry benchmarks placed the overall success rate at roughly 10 percent.
Drugs fail for many reasons. Some turn out to cause unacceptable side effects. Others simply don’t work well enough to beat a placebo or outperform existing treatments. Some show promise in early phases but can’t replicate those results in larger, more diverse populations. The timeline varies enormously too. While the median development time from first human study to marketing approval is 7.3 years, the fastest project in one large analysis took just 8 months, and the slowest stretched past 18 years.
What Participation Looks Like in Practice
If you’re considering joining a clinical trial, the experience will depend heavily on the phase and the condition being studied. Early-phase trials often require more frequent clinic visits, blood draws, and monitoring because researchers are still learning how the treatment behaves in the body. Later-phase trials may feel closer to routine medical care, with periodic check-ins and follow-up appointments spread over months or years.
You’ll typically go through a screening process to confirm you meet the eligibility criteria. If you qualify, you’ll review and sign the informed consent document, which isn’t a contract binding you to stay. It’s a record that you understood the study and agreed to participate at that point in time. From there, you’ll be assigned to a treatment or control group and follow the study’s schedule of visits, tests, or treatments. Throughout the process, a research team monitors your health and tracks any side effects. If the treatment causes problems or you simply change your mind, you can leave the study at any point.
Clinical trials can be found through databases like ClinicalTrials.gov, which lists thousands of active studies searchable by condition, location, and phase. Many hospitals, cancer centers, and academic medical institutions also maintain their own registries of trials currently recruiting participants.